For instance, the recently published Lu-PSMA trial reported on grade III/IV lymphopenia, thrombopenia, anemia, and neutropenia in up to 32% of the cases, whereas for the kidneys, only grade I/II events were reported in 10% of the treated patients [8]. This evidence concerns the gene FOLH1 and anemia (phenotype).